NCT07189377 Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
| NCT ID | NCT07189377 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Health Network, Toronto |
| Condition | Hepatitis B Virus (HBV) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-09-24 |
| Primary Completion | 2027-08 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
Eligibility Criteria
Donor Inclusion Criteria * Donor lung suitable for transplantation * HBV SAg positive and/or HBV NAT+ donor Donor Exclusion Criteria * HIV positive * HTLV 1/2 positive; * Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc). Recipient inclusion Criteria: * Recipients eligible and listed for lung transplant * HBV NAT negative * Provides written informed consent * Has received at least 3 prior doses of Hepatitis B vaccine or anti-HBs\>=10 IU/mL * Patients with other co-morbid conditions (such as diabetes, autoimmune disease, renal dysfunction) will remain eligible provided they are otherwise medically suitable for transplantation. The exception to this will be patients with significant liver disease as outlined below. Recipient exclusion Criteria: * Chronic liver disease with \> stage 2 fibrosis * Participating in another interventional clinical trial * Recipient listed for combined transplant (e.g.,